Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Chongxi Yu is currently active in the Biotechnology & Pharmaceuticals technology area. The portfolio has 1 pending office action, which is being reviewed by 1 distinct examiner. This indicates a focused level of activity within the patent office for their current pharmaceutical filings.
The examination is taking place in 1 distinct art unit. CORNET, JEAN P is identified as the busiest examiner, with 1 busiest examiner pending office action currently assigned. This 1 action is the only pending matter for the portfolio at this time. With 1 distinct examiner and 1 distinct art unit, the prosecution path is straightforward and centralized. The 1 pending office action represents the only current hurdle in the Biotechnology & Pharmaceuticals sector. Practitioners can focus their resources on 1 examiner to move the application forward and achieve the strategic goals for this intellectual property portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251336 | TOPICAL ADMINISTRATION OF 2-(DIETHYLAMINO)ETHYL 2-(4-ISOBUTYLPHENYL)PROPRIONATE FOR TREATMENT OF DISEASES | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18251336 | TOPICAL ADMINISTRATION OF 2-(DIETHYLAMINO)ETHYL 2-(4-ISOBUTYLPHENYL)PROPRIONATE FOR TREATMENT OF DISEASES | CORNET, JEAN P | 1628 | §103Other | Non-Final OA | — | Pending | May 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChongxi Yu has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jean P Cornet has the most, with 1 of Chongxi Yu's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
